Related by context. All words. (Click for frequent words.) 72 axitinib 72 motesanib 71 tremelimumab 70 pertuzumab 70 iniparib 70 ocrelizumab 70 elotuzumab 70 pomalidomide 69 Canvaxin 69 cediranib 69 neratinib 69 enzastaurin 69 drug figitumumab 69 Velcade bortezomib 68 vandetanib 68 temsirolimus 68 Xinlay 68 TACI Ig 68 Nuvion 68 BAY #-# 67 olaparib 67 ASA# 67 alvespimycin 67 rNAPc2 67 Asentar 67 HGS# 67 vicriviroc 66 midstage clinical 66 cilengitide 66 Nexavar sorafenib 66 ixabepilone 66 cangrelor 66 Vorapaxar 66 cabazitaxel 66 Dacogen injection 66 Folotyn 66 Aflibercept 66 Targretin 66 MyVax 66 lapatinib Tykerb 66 pazopanib 66 LUX Lung 66 midstage trials 65 mapatumumab 65 midstage studies 65 tasisulam 65 Arranon 65 sunitinib 65 sorafenib Nexavar 65 Avastin bevacizumab 65 Vectibix panitumumab 65 Dasatinib 65 sunitinib malate 65 bevacizumab Avastin 65 Xyotax 65 tofacitinib 65 abiraterone 65 regorafenib 65 Fablyn 65 Mylotarg 65 Torisel 65 alogliptin 65 AVERROES 65 teriflunomide 65 Tarceva erlotinib 65 YONDELIS 65 vemurafenib 65 recurrent glioblastoma multiforme 65 aflibercept 65 phase IIb trial 65 riociguat 65 GVAX 65 vorinostat 65 Plicera 65 tanespimycin 65 Mipomersen 65 STRIDE PD 65 phase IIb clinical 65 PSMA ADC 64 LAF# 64 BRAF inhibitor 64 PTK ZK 64 motavizumab 64 MGd 64 phase Ib 64 CBLC# 64 glufosfamide 64 tesmilifene 64 Troxatyl 64 Ocrelizumab 64 obatoclax 64 teplizumab 64 XL# SAR# 64 Zactima 64 muraglitazar 64 Amrubicin 64 Pertuzumab 64 XmAb# 64 SUTENT ® 64 Telcyta 64 Tolamba 64 dacetuzumab 64 gefitinib Iressa 64 adecatumumab 64 Alimta pemetrexed 64 HuMax CD4 64 NSABP C 64 trastuzumab DM1 64 Ceflatonin 64 dirucotide 64 Zolinza 64 docetaxel chemotherapy 64 panitumumab 64 Vandetanib 64 Phase Ib clinical 64 Affinitak 64 OvaRex ® MAb 64 HER2 positive metastatic breast 64 TBC# 64 darapladib 64 talabostat 64 Phase Ib study 64 BRIM2 63 T DM1 63 JAK inhibitor 63 erlotinib Tarceva 63 Cabazitaxel 63 ELACYT 63 ZACTIMA 63 zalutumumab 63 docetaxel Taxotere R 63 HuMax EGFr 63 cetuximab Erbitux 63 samalizumab 63 EndoTAGTM 1 63 Atrasentan 63 iclaprim 63 angiogenesis inhibitor 63 rindopepimut 63 registrational trial 63 mycophenolate mofetil 63 IMA# 63 Theratope 63 Vectibix 63 elesclomol 63 Prostate AdenoCarcinoma Treatment 63 Alzhemed 63 Tavocept 63 Herceptin trastuzumab 63 Novartis Zometa 63 APPRAISE 63 Ixempra 63 Hycamtin 63 rituximab Rituxan 63 daclizumab 63 Erbitux cetuximab 63 Vidaza azacitidine 63 solanezumab 63 ToGA 63 metastatic HRPC 63 Treanda 63 phase IIa clinical 63 EMPHASIS HF trial 63 natalizumab 63 nalbuphine ER 63 AEG# 63 trastuzumab DM1 T DM1 63 Temsirolimus 63 tafamidis 63 lenalidomide Revlimid 63 ganetespib 63 PEG SN# 63 MyVax personalized immunotherapy 63 MAGE A3 ASCI 63 experimental hepatitis C 63 zibotentan 63 Relovair 63 HCV SPRINT 63 CA4P 63 semagacestat 63 HuLuc# 63 tasocitinib 63 Zalbin 63 MIRCERA 63 UVIDEM 63 Neuvenge 63 blood clot preventer 63 galiximab 63 nonsmall cell lung cancer 63 elacytarabine 63 ZOLINZA 63 Yervoy 63 differentiated thyroid 63 Aplidin 63 Zybrestat 63 MMP inhibitors 63 Tyrima 63 HCD# [002] 62 atacicept 62 abiraterone acetate 62 Insegia 62 TELCYTA 62 SYMMETRY trial 62 gadobutrol 62 ACTIVE W 62 otelixizumab 62 FTY# 62 HQK 62 rolofylline 62 Clolar 62 PROSTVAC TM 62 panitumumab Vectibix 62 GSK# [002] 62 taranabant 62 Tocosol Paclitaxel 62 Vitaxin 62 TroVax ® 62 brivaracetam 62 Phase IIb clinical trials 62 Corlux 62 forodesine 62 SUTENT 62 goserelin 62 perampanel 62 relapsed ovarian cancer 62 Revlimid lenalidomide 62 Hepatocellular Carcinoma HCC 62 Nicole Onetto MD 62 mRCC 62 Zarnestra 62 Fibrillex TM 62 romiplostim 62 BZL# 62 OvaRex 62 CR# vcMMAE 62 PRT# 62 sargramostim 62 Gleevec imatinib 62 aleglitazar 62 decitabine 62 HCV RESPOND 2 62 atrasentan 62 thalidomide Thalomid 62 dexpramipexole 62 dalbavancin 62 multicenter Phase II 62 tocilizumab 62 mTOR inhibitor 62 dasatinib 62 Afatinib 62 Genasense 62 Tarceva TM 62 metastatic renal cell 62 Muraglitazar 62 sipuleucel T 62 Onrigin 62 Promacta 62 dexanabinol 62 Crizotinib 62 TELINTRA 62 phase IIb 62 peginesatide 62 lumiliximab 62 pivotal bioequivalence 62 gamma secretase inhibitor 62 Fludara 62 BCIRG 62 AVASTIN 62 Telintra 62 Advexin 61 CEQ# 61 hepatitis B vaccine Heplisav 61 arzoxifene 61 APEX AMI trial 61 Jevtana 61 PF # [002] 61 receptor tyrosine kinase inhibitor 61 Iressa gefitinib 61 eprotirome 61 SUCCEED trial 61 p# biomarker 61 vismodegib 61 anidulafungin 61 Tykerb lapatinib 61 Ceplene/IL-2 61 Panzem R NCD 61 drug PTK ZK 61 clazosentan 61 TTF Therapy 61 preclinically 61 vascular disrupting agent 61 nab paclitaxel 61 Celebrex celecoxib 61 Hydroxyurea 61 phase IIa 61 OHR/AVR# 61 Egrifta 61 Allovectin 7 61 PXD# 61 metastatic renal cell carcinoma 61 afatinib 61 Boceprevir 61 ofatumumab 61 telcagepant 61 Phase 2a trial 61 ospemifene 61 tanezumab 61 almorexant 61 ZD# [001] 61 lupus nephritis 61 Phase Ib II 61 TroVax 61 chemoradiotherapy 61 ELND# 61 bortezomib Velcade 61 standard chemotherapy regimen 61 EOquin TM phase 61 Acapodene 61 Galida 61 AGILECT R 61 oral prodrug 61 BRIM3 61 PROMACTA 61 heterozygous FH 61 Laquinimod 61 canagliflozin 61 OncoVex 61 MDV# 61 Enzastaurin 61 eritoran 61 sapacitabine 61 Femara letrozole 61 DSMB recommended 61 Dacogen decitabine 61 Onconase 61 alemtuzumab Campath 61 AVADO 61 Provenge prostate cancer 61 sorafenib 61 tramiprosate ALZHEMED TM 61 Viramidine 61 MabThera rituximab 61 Phase IIIb clinical 61 Alzhemed TM 61 GAMMAGARD 61 crizotinib PF # 61 Aptivus 61 Revlimid 61 proteasome inhibitor 61 assessing T DM1 61 blood thinner prasugrel 61 GnRH agonists 61 malignant pleural mesothelioma 61 glatiramer acetate 61 desvenlafaxine succinate 61 Phenoptin 61 prasugrel 61 ImClone Erbitux 61 RSR# 61 Aclidinium 61 Telavancin 61 fingolimod 61 VEGF Trap 61 Proxinium TM 61 Adenoma Prevention 61 Cimzia TM 61 romidepsin 61 warfarin therapy 61 Glufosfamide 61 TRISENOX 61 posaconazole 61 picoplatin 61 vaccine Stimuvax 61 Sorafenib 61 placebo controlled clinical 61 adalimumab Humira 61 efficacy endpoint 61 pain palliation 61 IRX 2 61 ancrod 61 relapsing MS 61 Actemra 61 Azedra 61 pegylated liposomal doxorubicin 61 midstage clinical trial 61 chemoprevention trials 61 ISEL 60 zanolimumab 60 Sprycel dasatinib 60 DEB# 60 lasofoxifene 60 farletuzumab 60 tolevamer 60 Stimuvax 60 GSK # 60 Myfortic 60 superficial bladder cancer 60 Dendreon Provenge 60 HGS ETR1 60 receptor inhibitor 60 TASKi3 60 NVA# 60 custirsen 60 mertansine 60 pediatric malignancies 60 Gleevec imatinib mesylate 60 Desmoteplase 60 SCH # 60 gemcitabine chemotherapy 60 Bezielle 60 lomitapide 60 deforolimus 60 Merck KGaA Erbitux 60 Bonefos 60 QTc prolongation 60 Recentin 60 baminercept 60 Bifeprunox 60 Pemetrexed 60 Vernakalant 60 letrozole 60 oral ridaforolimus 60 OPAXIO 60 GALNS 60 CRD5 60 Xelox 60 OMAPRO 60 APTIVUS 60 visilizumab 60 terlipressin 60 levosimendan 60 Rasagiline 60 TORISEL 60 RSD# oral 60 ximelagatran 60 Targretin capsules 60 Pegintron 60 GSK# [001] 60 metastatic castration resistant 60 phase IIIb 60 infliximab Remicade 60 Lu AA# 60 randomized Phase IIb 60 VA# [002] 60 oral antiplatelet 60 Golimumab 60 investigational hepatitis C 60 metastatic lung cancer 60 gemcitabine Gemzar ® 60 Trabectedin 60 LymphoStat B 60 alemtuzumab 60 Actilon 60 Fx #A 60 ruboxistaurin 60 platinum refractory 60 HuMax CD# 60 depsipeptide 60 PhG alpha 1 60 Phase III randomized controlled 60 alvimopan 60 apremilast 60 DXL# 60 sunitinib Sutent 60 trastuzumab Herceptin 60 Reverset 60 Phase 2b trial 60 Deforolimus 60 investigational humanized monoclonal antibody 60 NATRECOR R 60 Phase IIb trials 60 Phase #b/#a 60 Cerovive 60 AZILECT ® 60 Eribulin 60 metastatic hormone refractory 60 Virulizin ® 60 Tykerb 60 Noxafil 60 Ontak 60 molecularly targeted 60 epigenetic therapies 60 cannabinor 60 IMC A# 60 NSCLC 60 Removab 60 MYDICAR 60 pradefovir 60 relapsed MM 60 BLP# 60 alkylating agent 60 Cloretazine 60 chemopreventive agent 60 Orathecin 60 REG1 60 Tesmilifene 60 Certolizumab pegol 60 tramiprosate Alzhemed TM 60 postmenopausal estrogen 60 PrevOnco ™ 60 CALGB # [001] 60 blood thinner apixaban 60 methylnaltrexone 60 ridaforolimus 60 TNFerade 60 gefitinib 60 OncoVEX GM CSF 60 efalizumab 60 Panzem 60 sitaxsentan 60 Panitumumab 60 metastatic colorectal 60 NV1FGF 60 bicifadine 60 multicenter Phase 60 Sutent sunitinib 60 phase IIb study 60 beta blocker therapy 60 Avastin Tarceva 60 pralatrexate 60 midstage clinical trials 60 chemotherapeutic regimen 60 Kynapid 60 SGS# 60 mipomersen 60 oral methylnaltrexone 60 Phase #/#a trial 60 Teriflunomide 60 ORENCIA R 60 docetaxel Taxotere 60 Apixaban 60 AZD# 60 cytokine refractory 60 Committee IDMC 60 ThGRF 60 Celgene Revlimid 60 Phase IIa trials 60 Bayer HealthCare Onyx Pharmaceuticals 60 BCX# 60 indolent NHL 60 indibulin 60 QVA# 59 ProSavin 59 TEMODAL 59 Lapatinib 59 IGF IR 59 triphendiol 59 mGluR2 NAM 59 FDA Oncologic Drugs 59 IMC #B 59 Rilonacept 59 Amigal 59 Tanespimycin 59 orBec 59 Cloretazine ® 59 EndoTAG TM -1 59 EGFR inhibitors 59 TLK# 59 PREOS 59 torcetrapib atorvastatin 59 Votrient 59 canakinumab 59 myelodysplastic syndromes 59 trastuzumab emtansine T DM1 59 crizotinib 59 bosutinib 59 PROSTVAC ® 59 cardiotoxicity 59 RRMS patients 59 PRIMO CABG2 59 CYT# potent vascular disrupting 59 Vilazodone 59 Lantus insulin 59 tarenflurbil 59 Syncria 59 Cinquil 59 anti androgen 59 IMPACT IMmunotherapy 59 ularitide 59 NP2 Enkephalin 59 Prosaptide 59 volociximab 59 medically inoperable 59 eltrombopag 59 GW# [003] 59 cetuximab 59 SinuNase 59 idiopathic pulmonary fibrosis IPF 59 Trexima 59 DFMO 59 anakinra 59 APEX PD 59 PDE4 inhibitor 59 Sym# 59 eniluracil 59 Retaane 59 imetelstat 59 PD LID 59 metaglidasen 59 Quinamed 59 aromatase inhibitors AIs 59 carfilzomib 59 PRIMO CABG 59 Phase IIIb study 59 reslizumab 59 Sibutramine Cardiovascular Outcomes 59 Phase IIa trial 59 fostamatinib 59 aflibercept VEGF Trap 59 ASONEP 59 opioid induced bowel dysfunction 59 antiplatelet therapy 59 Itopride 59 Prestara 59 senicapoc 59 Taxotere docetaxel 59 bifeprunox 59 RoACTEMRA 59 subcutaneous PRO 59 integrase inhibitor 59 AstraZeneca Iressa 59 Hematide 59 radiation sensitizer 59 Rituxan rituximab 59 RhuDex 59 Zevalin consolidation 59 ACZ# 59 ELCAP 59 vinflunine 59 Natalizumab 59 Specifid 59 FOLFIRINOX 59 Sutent sunitinib malate 59 Allovectin 7 ® 59 Board DSMB 59 budesonide foam 59 NSABP 59 Pimavanserin 59 paclitaxel Taxol ® 59 SERMs 59 Degarelix 59 Archexin 59 novel oral anticoagulant 59 Potiga 59 Arcalyst 59 HAART regimens 59 selective modulator 59 taxane chemotherapy 59 PRECISE Trial 59 Intuniv 59 Genz # 59 antiplatelet agent 59 Omapro 59 paclitaxel Taxol 59 idraparinux 59 gemcitabine Gemzar 59 PEG Interferon lambda 59 Alfimeprase 59 PegIntron 59 liposomal doxorubicin 59 LY# [003] 59 Abiraterone acetate 59 Subgroup analysis 59 fulvestrant 59 mg/m2 cohort 59 CoFactor 59 NovoTTF 59 Vertex telaprevir 59 Bevacizumab 59 Gattex 59 squalamine 59 RSD# 59 Symadex 59 Phase 2b study 59 bendamustine 59 metastatic CRC 59 ACTEMRA TM 59 infusional 5-FU/LV 59 RIGScan CR 59 Safinamide 59 IFN beta 59 confirmatory Phase III 59 CUSTOM III 59 Faslodex 59 ambrisentan 59 INCB# [001] 59 Rezular 59 MADIT II 59 ongoing Phase 1b 59 Ambrisentan 59 MK #B 59 amrubicin 59 CIMZIA TM 59 dose escalation Phase 59 denosumab 59 capecitabine Xeloda R 59 recurrent GBM 59 corticosteroid dexamethasone 59 gastrointestinal stromal tumor GIST 59 Phase Ib clinical trials 59 velafermin 59 immunomodulatory therapy 59 coinfected patients 59 acyclovir Lauriad R 59 interferon therapy 59 Omnitarg 59 NM# [003] 59 FOLFIRI chemotherapy 59 ADVANCE PD 59 oral anticoagulants 59 mTOR inhibitors 59 Diamyd ® 59 Amgen Vectibix 59 GRNVAC1 59 FOLFOX chemotherapy 59 Genentech Herceptin 59 antithrombotic therapy 59 Erbitux 59 Gilenia 59 ALK inhibitors 59 MEK inhibitor RDEA# 59 chronic lymphocytic leukemia CLL 59 prostate cancer mCRPC 59 randomized discontinuation trial 59 Exemestane 59 oral antiviral 59 registrational 59 Tasigna nilotinib 59 ONCONASE R 59 Vicriviroc 59 Neurodex 59 metastatic RCC 59 Avastin adjuvant 59 lenalidomide dexamethasone 59 Doxil ® 59 dose escalation phase 59 PARP inhibitor 59 Romiplostim 59 anti leukemic 59 L BLP# 59 anti TNF 59 cardiac toxicity 59 Capesaris 59 CYPHER Stent 59 MERLIN TIMI 59 standard chemotherapy regimens 59 RG# [001] 59 ipilimumab 58 masitinib 58 neoadjuvant treatment 58 CLARITY study 58 Vidofludimus 58 ustekinumab 58 Carfilzomib 58 SU# [003] 58 Viprinex 58 sorafenib tablets 58 Aryplase 58 verteporfin 58 NO# [002] 58 lesinurad 58 Mirapexin 58 aprepitant 58 Xanafide 58 relapsed MCL 58 squamous non 58 virus HCV protease inhibitor 58 CytoFab 58 Avastin 58 VADT 58 DPP4 inhibitor 58 gepirone ER 58 velaglucerase alfa 58 taspoglutide 58 clevudine 58 Aurora kinase inhibitor 58 Orexigen Contrave 58 ATL/TV# 58 Tarvacin 58 Sulonex 58 Peginterferon alfa 2b 58 blinatumomab 58 Cytoxan 58 Pfizer Sutent 58 pharmacodynamic effects 58 histone deacetylase HDAC inhibitor 58 JAK inhibitors 58 Arzerra 58 evaluating tivozanib 58 ponatinib 58 Avanafil 58 TNF antagonist 58 Arixtra 58 midstage study 58 nilotinib 58 Inhaled nitric oxide 58 adjuvant colon cancer 58 mg kg dose 58 HGS ETR2 58 Stimuvax R 58 Fodosine 58 Tasimelteon 58 Byetta exenatide 58 Sprycel 58 imatinib Gleevec 58 multiple myeloma MM 58 BRAF V#E mutation 58 cytotoxic chemotherapy 58 Iressa 58 CytoFabTM 58 CLL SLL 58 agomelatine 58 viral kinetics 58 investigational monoclonal antibody 58 teduglutide 58 colorectal cancer liver metastases 58 statin medications 58 surrogate endpoint 58 IV NSCLC 58 H. pylori eradication 58 Olaparib 58 TNF blocker therapy 58 OZURDEX ® 58 ZYBRESTAT fosbretabulin 58 tramiprosate 58 docetaxel Taxotere ® 58 Degludec 58 pharmacokinetic PK study 58 Nexavar ® 58 VNP#M 58 irbesartan 58 glatiramer acetate Copaxone 58 rhThrombin 58 XELOX 58 ImmunoVEX HSV2 58 SIMPADICO trial 58 torezolid phosphate 58 Hematide ™ 58 castrate resistant prostate cancer 58 systemic ALCL 58 PARP inhibitors 58 EGFR TKI 58 randomized multicenter Phase III 58 BEXXAR Therapeutic Regimen 58 taxane refractory 58 metastatic malignant 58 odanacatib 58 IIa trial 58 EXJADE 58 IL# PE#QQR 58 grade cervical intraepithelial 58 BLP# Liposome Vaccine 58 peginterferon 58 bardoxolone methyl 58 RE LY 58 Fusilev 58 ONGLYZA ™ 58 pirfenidone 58 OvaRex R 58 PDE# inhibitors 58 PLX# 58 AML acute myeloid 58 factor Xa 58 androgen deprivation 58 MGCD# clinical trials 58 Nebido 58 pharmacodynamic markers 58 oral deforolimus 58 flavopiridol 58 miglustat 58 proteasome inhibitor bortezomib 58 intermittent dosing 58 R#/MEM # 58 calcineurin inhibitors 58 K ras 58 Traficet EN 58 IV bisphosphonates 58 preoperative chemotherapy 58 belatacept 58 IGF 1R inhibitor 58 Cloretazine R VNP#M 58 Annamycin 58 Rigel R# 58 IV metastatic melanoma 58 EVIZON 58 ABSORB trial 58 MKC# MKC# PP 58 Elocalcitol 58 Vectibix monotherapy 58 SRT# [003] 58 concurrent chemoradiation 58 pegylated interferons 58 bapineuzumab 58 PTK# 58 palifosfamide 58 Silodosin 58 Akt activation 58 exemestane 58 Neuradiab 58 uric acid lowering 58 pramlintide 58 eculizumab 58 Phase #/#a 58 Hematologic 58 MDS AML 58 rEV# 58 subcutaneous formulation 58 capecitabine Xeloda 58 rilonacept 58 inhibitor RG# 58 valopicitabine 58 pharmacodynamics PD 58 genotypic resistance 58 trabectedin 58 Heplisav 58 metastatic malignant melanoma 58 refractory AML 58 SCCHN 58 DACH platinum 58 refractory acute myeloid 58 Kantarjian 58 postoperative chemotherapy 58 Alessandro Riva 58 dasatinib Sprycel 58 investigational compound 58 antibody MAb 58 AZILECT R 58 hormone refractory prostate cancer 58 Saforis 58 incyclinide 58 torcetrapib 58 SNT MC# 58 MAXY alpha 58 CHOP chemotherapy 58 pharmacokinetic PK 58 enoximone 58 lorvotuzumab mertansine 58 etanercept Enbrel 58 intravenous bisphosphonates 58 rFVIIa 58 CB1 antagonists 58 darusentan 58 ALS #-# 58 viral kinetic 58 Aromasin 58 lintuzumab SGN 58 Tolvaptan 58 adipiplon 58 necitumumab 58 INCB# [003] 58 Oglemilast 58 erlotinib Tarceva ® 58 lintuzumab 58 Pirfenidone 58 Taxotere ® 58 bone metastasis 58 metastatic colorectal cancer 58 CIMZIA ™ 58 Nuedexta 58 multi kinase inhibitor 58 celgosivir 58 Motesanib 58 maraviroc 58 adjuvant chemotherapy 58 REMINYL ® 58 vorapaxar 58 adjuvant radiotherapy 58 TNF inhibitors 58 Phase #b/#a trial 58 ISTODAX 58 Smac mimetics 58 Tocosol 58 heavily pretreated 58 bevacizumab 58 GED aPC 58 Bicifadine 58 Dalbavancin 58 antiangiogenic therapy 58 lapatinib 58 Roche Xeloda 58 DSMB 58 nilotinib Tasigna 58 CDP# 58 dose escalation clinical 58 CCX# 58 tamoxifen therapy 58 KRAS status 58 vidofludimus 58 synthetic retinoid 58 Certican 58 Daclizumab 58 urocortin 2 58 evaluating Nexavar 58 pemphigus vulgaris 58 immune modulating 58 Eculizumab 58 thromboembolic disease 58 KIACTA ™ 58 ofatumumab HuMax CD#